STOCK TITAN

Takeda Pharmaceutical Company (TAK) Stock News, Nov 2020-Jan 2021

TAK NYSE

Takeda Pharmaceutical Company Limited reports news as a Japan-based, R&D-driven biopharmaceutical company whose American depositary shares trade under TAK. Its updates center on medicines and pipeline programs in gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines, including ENTYVIO, GAMMAGARD LIQUID ERC, HYQVIA, TAK-881, zasocitinib, rusfertide and oveporexton.

Recurring developments include pivotal clinical trial data, U.S. FDA regulatory actions involving new drug applications, prescription product availability, collaboration updates, and financial reports. Takeda also reports on launch preparation, generic competition affecting established products, operating-cost discipline, foreign-exchange effects, corporate transformation initiatives and governance matters tied to its global pharmaceutical business.

Rhea-AI Summary

Takeda Pharmaceutical Company Limited (NYSE:TAK) has received recognition in the 2021 Access to Medicine Index, ranking sixth overall among 20 pharmaceutical companies. The company excelled in Governance of Access, R&D capacity, and health system strengthening. Notably, Takeda ranked first in Governance of Access and led the industry for R&D capacity building. Its initiatives focus on affordable access, assessed access strategies, and local healthcare programs, such as the Blueprint for Innovative Healthcare Access in Kenya and Rwanda, aimed at enhancing medicine accessibility.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
none
-
Rhea-AI Summary

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) provided a comprehensive update during the 39th Annual J.P. Morgan Healthcare Conference. CEO Christophe Weber highlighted Takeda's strong business resilience amid COVID-19 and outlined plans for revenue growth through an innovative pipeline, targeting JPY5 trillion ($47 billion) by FY2030. Key programs, including TAK-003 for dengue and TAK-755 for thrombotic thrombocytopenic purpura, are expected to contribute significantly to revenue. Takeda aims to maintain investment-grade credit ratings, with a focus on cost synergies and shareholder returns.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
none
Rhea-AI Summary

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is set to participate in the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021. The virtual presentation will take place at 5:20 p.m. ET and will feature CEO Christophe Weber. Investors and the public can access the live webcast here. A replay and downloadable slides will also be available on Takeda's website following the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
conferences
-
Rhea-AI Summary

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has successfully concluded the sale of a non-core portfolio of 16 prescription products to Cheplapharm for $562 million. This divestment, originally announced in September 2020, aligns with Takeda's strategy to streamline its focus on key therapeutic areas including Gastroenterology and Oncology. Proceeds from the sale will be allocated towards reducing debt, aiming for a net debt/adjusted EBITDA ratio of 2x by 2023. Takeda has exceeded its $10 billion divestiture goal with a total of 11 deals worth approximately $11.6 billion since January 2019.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
none
-
Rhea-AI Summary

Takeda Pharmaceutical Company has agreed to divest a non-core portfolio of prescription pharmaceutical products in China to Hasten Biopharmaceutic Co., Ltd. for $322 million. This portfolio, which generated approximately $109.5 million in sales during FY2019, includes cardiovascular products like Ebrantil. The divestiture aligns with Takeda's strategy to focus on core therapeutic areas such as Gastroenterology and Oncology. Proceeds will be used to reduce debt and support long-term growth, with over 15 product approvals planned in China over the next five years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
none
Rhea-AI Summary

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced FDA approval for the supplemental New Drug Application (sNDA) of ICLUSIG® (ponatinib) for adults with chronic-phase chronic myeloid leukemia (CML) who are resistant or intolerant to at least two prior kinase inhibitors. The updated regimen features a starting dose of 45 mg, reducing to 15 mg upon achieving ≤1% BCR-ABL1IS. The approval is based on data from the OPTIC and PACE trials. The revised label is expected to optimize treatment for patients with resistant CML, providing significant clinical benefits.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
-
Rhea-AI Summary

Prime Therapeutics has secured an agreement with Takeda Pharmaceuticals for its hemophilia A treatment, ADVATE. This collaboration aims to evaluate clinical outcomes and costs associated with hemophilia A treatments, which have become increasingly expensive. The agreement introduces a health plan remuneration model linked to quantifiable medical costs from ineffective treatments under a total cost of care framework. Hemophilia A affects around 80% of the 18,000 people living with the disorder in the U.S., presenting an opportunity for improved patient and cost outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
none
-
Rhea-AI Summary

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced that the FDA has accepted its New Drug Application for TAK-721, a treatment for eosinophilic esophagitis (EoE), granting it Priority Review. If approved, TAK-721 will be the first FDA-approved therapy for EoE. The product had previously received Breakthrough Therapy and Orphan Drug designations. The NDA filing is based on successful Phase 3 trials demonstrating its safety and efficacy. EoE affects approximately 1 in 2,000 people in the U.S., leading to significant quality of life impacts due to related symptoms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
none
Rhea-AI Summary

Takeda Pharmaceutical Company Limited (TAK) has completed the sale of a portfolio of 18 pharmaceutical and OTC products to Celltrion Inc. for $278 million, including milestone payments. This divestment, part of Takeda's strategy to focus on core areas, is expected to aid in reducing debt and accelerating deleveraging to achieve a net debt/adjusted EBITDA target of 2x by FY 2023. The sale comes after Takeda exceeded its $10 billion non-core asset divestiture target, totaling ~$11.3 billion in agreements since January 2019.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
none

FAQ

What is the current stock price of Takeda Pharmaceutical (TAK)?

Takeda Pharmaceutical (TAK) last closed at $21.77.

What is the market cap of Takeda Pharmaceutical (TAK)?

The market cap of Takeda Pharmaceutical (TAK) is approximately $69.6B.